NCT05403385
Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer treatment 2 recruiting NCT05859217
A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1) treatment 2 not_yet_recruiting NCT05478538
Observational Lung Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform No drug interventions Not Available Not Available recruiting NCT05299125
Amivantamab, Lazertinib, and Pemetrexed for First-line Treatment of Recurrent/Metastatic Non-small Cell Lung Cancers With Epidermal Growth Factor Receptor Mutations treatment 2 recruiting NCT06228482
Molecularly Targeted Radionuclide Therapy Via the Integrin Alphavbeta6 treatment 1 recruiting NCT03825510
Immunotherapy SBRT Sensitization of the Programmed Death-1 (PD-1) Effect No drug interventions treatment 2 completed NCT03987555
Paclitaxel Therapeutic Drug Monitoring in Cancer Patients No drug interventions Not Available Not Available recruiting NCT03512847
Predictive Gene Profiles and Dynamic Measurement of Treatment Response in Metastatic Non-small Cell Lung Cancer No drug interventions Not Available Not Available completed NCT03415126
A Study of ASN007 in Patients With Advanced Solid Tumors No drug interventions treatment 1 completed NCT01438307
Phase II Study of Cabazitaxel-XRP6258 in Advanced Non-Small Cell Lung Cancer treatment 2 completed NCT02983500
Patient Reported Outcomes Registry in Patient With Cancer Cachexia No drug interventions Not Available Not Available completed NCT05617313
Study of GT103 in Combination With Pembrolizumab in Refractory, Metastatic Non-Small Cell Lung Cancer treatment 2 active_not_recruiting NCT04170634
Tumoral Bone Strength Assessment by Numerical Simulation Using Quantitative CT : the MEKANOS Study No drug interventions Not Available Not Available recruiting NCT03589339
NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy treatment 1 recruiting NCT05480865
SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation treatment 1 recruiting NCT06159790
A Study to Compare Efficacy, Safety, and Immunogenicity of GME751 and EU-authorized Keytruda in Adult Participants With Untreated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) treatment 3 recruiting NCT05091190
Immunotherapy Clearance and Phenotype of Circulating Tumor Cells in Lung and Head and Neck Cancers No drug interventions other Not Available recruiting NCT05255302
De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction treatment 2 / 3 recruiting NCT04615884
Use of Chinese Herbal Formula Shu Yu Wan in Lung Cancer Patients No drug interventions supportive_care Not Available withdrawn NCT04846452
Sintilimab, Anlotinib Hydrochloride and Platinum-Containing Dual-Agent Chemotherapy in NSCLC treatment 2 unknown_status NCT05848739
A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors treatment 1 recruiting NCT03417882
GRN-1201 With Pembrolizumab in Subjects With Metastatic PD-L1+ NSCLC treatment 2 terminated NCT05339568
Patient's Whole Process Follow-up Management(HOPE-1) No drug interventions Not Available Not Available recruiting NCT04120454
Ramucirumab and Pembrolizumab for the Treatment of EGFR Mutant Recurrent or Metastatic Non-small Cell Lung Cancer treatment 2 active_not_recruiting NCT04751747
Adaptive Radiation Planning for the Reduction of Radiation-Induced Toxicity in Patients With Stage II-IV Non-small Cell Lung Cancer No drug interventions supportive_care Not Available recruiting NCT04250545
Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer treatment 1 active_not_recruiting NCT04227028
Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLC treatment 1 active_not_recruiting NCT04285671
Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer treatment 1 / 2 active_not_recruiting NCT05377788
Lazertinib Real-world Observational Study of in Pre-treated EGFR T790M Mutant With Advanced Non-small Cell Lung Cancer Not Available Not Available unknown_status NCT04186988
[18F]-AraG for the Detection of T-Cell Activation in Advanced Non-small Cell Lung Cancer Patients Undergoing PD-1/PD-L1-Directed Therapy No drug interventions diagnostic 0 withdrawn NCT03134456
Pembrolizumab for Metastatic NSCLC Patients Expressing PD-L1 Who Have Their Own PDX treatment 4 recruiting NCT05840770
Cemiplimab for the Treatment of Untreated Brain Metastases From PD-L1 >= 50% Non-Small Cell Lung Cancer treatment 2 recruiting NCT06349642
Predicting Response to Immune Checkpoint Inhibitors Across Solid Tumors Using a Live Tumor Diagnostic Platform No drug interventions Not Available Not Available recruiting NCT04940299
Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma treatment 2 active_not_recruiting NCT04762199
MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer treatment 1 recruiting NCT02498613
A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors treatment 2 active_not_recruiting NCT05786924
A Study of BDTX-4933 in Patients With KRAS, BRAF and Select RAS/MAPK Mutation-Positive Cancers No drug interventions treatment 1 recruiting NCT02589522
Testing the Safety of M6620 (VX-970) When Given With Standard Whole Brain Radiation Therapy for the Treatment of Brain Metastases From Non-small Cell Lung Cancer, Small Cell Lung Cancer, or Neuroendocrine Tumors treatment 1 active_not_recruiting NCT05570825
SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer treatment 2 recruiting NCT06518057
Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast Cancer or Non-small Cell Lung Cancer No drug interventions treatment 2 not_yet_recruiting NCT05935774
OT-101 in Combination With Atezolizumab for the Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer treatment 2 withdrawn NCT06249282
Carfilzomib in Combination With Sotorasib for the Treatment of Patients With KRAS G12C Mutated Advanced or Metastatic Non-small Cell Lung Cancer treatment 1 recruiting NCT04007744
Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors treatment 1 recruiting NCT03600701
Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer treatment 2 active_not_recruiting NCT02971501
Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases treatment 2 active_not_recruiting NCT05045404
Poziotinib and Ramucirumab for the Treatment of EGFR Exon 20 Mutant Stage IV Non-small Cell Lung Cancer treatment 2 withdrawn NCT06472804
Insomnia in Patients With Metastatic Lung Cancer No drug interventions Not Available Not Available recruiting NCT04789668
Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases treatment 1 / 2 completed NCT04919369
All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer treatment 1 recruiting NCT05435846
Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation treatment 1 terminated NCT05269381
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors treatment 1 / 2 recruiting NCT02419495
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies treatment 1 active_not_recruiting NCT06500455
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain No drug interventions treatment 3 not_yet_recruiting NCT02888743
Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer treatment 2 active_not_recruiting NCT02955290
CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer treatment 1 / 2 recruiting NCT05256290
Phase 1/2 Study of BDTX-1535 in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations No drug interventions treatment 1 / 2 recruiting NCT03225664
Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic, Unresectable, or Locally Advanced treatment 1 / 2 active_not_recruiting NCT04533451
Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older With Advanced Non-small Cell Lung Cancer treatment 2 active_not_recruiting NCT04639245
Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer treatment 1 / 2 terminated NCT05234307
PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer treatment 1 recruiting NCT03025256
Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease treatment 1 active_not_recruiting NCT03808337
Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease No drug interventions treatment 2 recruiting NCT03831932
Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer treatment 1 / 2 active_not_recruiting NCT06043713
Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Pancreatic, Colorectal and Non-Small Cell Lung Cancers With KRAS G12V Mutations treatment 1 recruiting NCT02444741
Pembrolizumab and Stereotactic Body Radiation Therapy or Non-Stereotactic Wide-Field Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer treatment 1 / 2 active_not_recruiting NCT04197934
WSD0922-FU for the Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases treatment 1 recruiting NCT04837716
Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung Cancer treatment 1 active_not_recruiting NCT05440916
Palliative RadIotherapy of Multiple Metastatic Sites Before First Line of Systemic Therapy With Immune Checkpoint Inhibitors and Chemotherapy in Metastatic Non-Small-Cell Lung Cancer No drug interventions treatment 2 recruiting NCT03892096
Development of a Cell Free DNA Assay as a Biomarker for Predicting Early Non-response to Therapy in Metastatic Cancer No drug interventions Not Available Not Available completed NCT02496663
Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor treatment 1 active_not_recruiting NCT04925986
Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-NaĂŻve PD-L1+ Non-Squamous NSCLC treatment 2 terminated NCT02503722
Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung Cancer treatment 1 active_not_recruiting NCT02595866
Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer treatment 1 completed NCT06067776
Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer treatment 1 not_yet_recruiting NCT05334329
Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors treatment 1 active_not_recruiting NCT01932489
The Jules Bordet Institute Molecular Profiling Program Feasibility Trial No drug interventions other Not Available completed NCT05498389
EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer treatment 1 / 2 not_yet_recruiting NCT02706392
Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies No drug interventions treatment 1 terminated NCT04151940
PET/CT Changes During Chemoimmunotherapy and Radiation Therapy in Patients With Stage IV Non-small Cell Lung Cancer No drug interventions other Not Available recruiting NCT04780568
Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer treatment 1 recruiting NCT04588246
Testing the Addition of Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in People With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery treatment 3 recruiting NCT06500481
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial No drug interventions treatment 3 not_yet_recruiting NCT02409108
Perfusion-Induced Hyperthermia for Metastatic Carcinoma No drug interventions device_feasibility Not Available completed NCT04514484
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV treatment 1 active_not_recruiting NCT05853887
Liquid Biopsy Based NGS in Newly Diagnosed NSCLC No drug interventions health_services_research Not Available recruiting NCT06517433
First-in-Human Dose Escalation Study of XMT-1536 in Cancers Likely to Express NaPi2b treatment 1 completed NCT04511533
Dacomitinib for Treatment of Patients in India With Metastatic Non Small Cell Lung Cancer With EGFR Activating Mutations treatment 4 completed NCT02967133
A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer treatment 2 terminated NCT05274451
A Study to Investigate LYL797 in Adults with Solid Tumors No drug interventions treatment 1 recruiting NCT01656551
MILES-4: Study Comparing Gemcitabine and Pemetrexed, With or Without Cisplatin, in Patients With Nonsquamous Lung Cancer treatment 3 active_not_recruiting NCT06068153
AMG510 (Sotorasib) Plus Lenvatinib as Second-line Treatment in Patients With KRASG12C Mutant, Metastatic NSCLC treatment 2 withdrawn NCT03727477
Efficacy of Treatment Sequences in Patients With Non-small Cell Lung Cancer Receiving Lorlatinib No drug interventions Not Available Not Available completed NCT04868877
Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination treatment 1 / 2 recruiting NCT05889247
Circulating Tumor DNA Guided Treatment Monitoring in Advanced Lung Cancer No drug interventions treatment Not Available recruiting NCT05226598
Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007) treatment 3 active_not_recruiting NCT04743505
Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC) treatment 1 / 2 recruiting NCT05111197
Local Ablative Stereotactic Radiotherapy for Residual Hypermetabolic Lesion in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Long-term Responders to Immunotherapy No drug interventions treatment 3 recruiting NCT03004183
SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC treatment 2 completed NCT05675683
Real-World Assessment of Clinical Outcomes in Metastatic NSCLC Patients With MET Exon 14 Skipping Mutation and Brain Metastases Treated With Capmatinib Not Available Not Available completed NCT04951583
Fecal Microbial Transplantation Non-Small Cell Lung Cancer and Melanoma No drug interventions treatment 2 active_not_recruiting NCT03123783
CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab treatment 1 / 2 completed NCT06473961
A Phase â… b Study on Autologous GC101 TIL Injection for the Treatment of NSCLC treatment 1 not_yet_recruiting NCT04836728
Study of Chemotherapy and PD-1 Inhibitor Combination With Autologous CIK Cell Immunotherapy to Treat Lung Cancer treatment 2 unknown_status NCT03304093
Immunotherapy by Nivolumab for HIV+ Patients treatment 2 completed NCT05689671
Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma treatment 4 recruiting NCT04725188
Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002, KEYVIBE-002) treatment 2 active_not_recruiting NCT03810807
Study of Dacomitinib and Osimertinib for Patients With Advanced EGFR Mutant Lung Cancer treatment 1 active_not_recruiting NCT01773109
Etirinotecan Pegol (NKTR-102) in NSCLC treatment 2 completed NCT04154956
SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients treatment 3 active_not_recruiting NCT03436056
PembRolIzuMab and Stereotactic Body Radiotherapy In Metastatic Non-small-cell lunG Cancer Patients treatment 1 terminated NCT02793856
PD-1 Knockout Engineered T Cells for Metastatic Non-small Cell Lung Cancer treatment 1 completed NCT03715985
Personalized Neo-antigen Vaccine in Advanced Solid Tumors (NeoPepVac) No drug interventions treatment 1 / 2 unknown_status NCT03363685
Verification of Novel Survival Prediction Algorithm for Patients With NSCLC Spinal Metastasis No drug interventions Not Available Not Available unknown_status NCT03307785
Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 treatment 1 active_not_recruiting NCT03300115
Clinical Trial of the Efficacy and Safety of AC0010 in the Treatment of EGFR T790M Patients With Advanded NSCLC treatment 2 unknown_status NCT04793815
Lung Cancer Cryo-Activation as a Novel Approach to Augment Immunotherapy Efficacy (CRYOVATE) treatment Not Available completed NCT05722015
A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77) treatment 3 active_not_recruiting NCT04471415
Study to Investigate DRP-104 in Adults With Advanced Solid Tumors treatment 1 / 2 terminated NCT03774732
PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer treatment 3 recruiting NCT05278052
Standard Maintenance Therapy (SMT) vs Local Consolidative Radiation Therapy and SMT in OM-NSCLC No drug interventions treatment 3 recruiting NCT03907852
Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer treatment 1 / 2 active_not_recruiting NCT01574300
Collaborative Advanced Stage Tissue Lung Cancer (CASTLE) Network No drug interventions Not Available Not Available terminated NCT03976375
Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008) treatment 3 active_not_recruiting NCT04623775
A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) treatment 2 active_not_recruiting NCT03845270
Her2-positive Lung Cancer Treated With Dedicated Drug treatment 2 completed NCT06083870
An Early Stage Study to Evaluate Oba01 for Injection in Patients With DR5 Positive LA/mNSCLC No drug interventions treatment 1 recruiting NCT02376699
Safety Study of SEA-CD40 in Cancer Patients treatment 1 terminated NCT03240549
Effectiveness and Safety of Adding Bevacizumab to First Line Chemotherapy in Lung Cancer Patients With Stable Disease treatment 2 unknown_status NCT03916913
TKI Followed by Thoracic Radiotherapy for Stage IV EGFR Mutant NSCLC No drug interventions treatment Not Available unknown_status NCT05110118
Pharmacokinetic Characteristics, Safety, Tolerability and Immunogenicity of LY01008 and Avastin in Healthy Chinese Male Subjects treatment 1 completed NCT05259319
Study Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan (IMMUNOs-SBRT) treatment 1 recruiting NCT02959619
Ensartinib in Non-small Cell Lung Cancer Patients With Positive ALK treatment 1 completed NCT04646824
Almonertinib With Chemotherapy in mEGFR NSCLC treatment 2 unknown_status NCT02946216
ALK/ROS1/MET Mutations on Plasma ctDNA in Patients With NSCLC No drug interventions Not Available Not Available unknown_status NCT06100796
Effect of DM on Outcomes and Response Rate in Patients With Advanced NSCLC on ICI Not Available Not Available recruiting NCT00701558
A Study of First Line Treatment With Tarceva (Erlotinib) in Combination With Gemcitabine in Patients With Unresectable Advanced and/or Metastatic Non-Small Cell Lung Cancer treatment 2 completed NCT01395758
Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer treatment 2 completed NCT01473563
A Study of Home Administration of Pemetrexed as Maintenance Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) Not Available 2 completed NCT04009122
Evaluation of the Quality of Life of Patients With Metastatic Non-small Cell Lung Cancer With Supplementary Therapy With IGEN-0206 No drug interventions treatment Not Available completed NCT05638425
Radiotherapy Combined With PD-1 Inhibitors and Chemotherapy in the Treatment of NSCLC Patients With Symptomatic Brain Metastases No drug interventions Not Available Not Available recruiting NCT05985330
Pilot Study of the Contribution of Fractional Exhaled Nitric Oxide as a Prognostic Marker of Response to Anti-PD-L1 Immunotherapy in Non-small Cell Lung Cancer No drug interventions Not Available Not Available not_yet_recruiting NCT02542930
Abscopal Effect for Metastatic Non-small Cell Lung Cancer. treatment 2 withdrawn NCT02411448
A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY) treatment 3 active_not_recruiting NCT02623257
EGFR Mutations on ctDNA in Patients With Advanced NSCLC No drug interventions Not Available Not Available completed NCT05999357
JDQ443 for KRAS G12C NSCLC Brain Metastases No drug interventions treatment 2 withdrawn NCT03477474
Registry of Guardant360® Use and Outcomes In People With Advanced Cancer No drug interventions Not Available Not Available terminated NCT05429320
A Study of Local Ablative Therapy (LAT) in People With Non-Small Cell Lung Cancer (NSCLC) No drug interventions treatment 2 recruiting NCT04082182
MIDRIX4-LUNG Dendritic Cell Vaccine in Patients With Metastatic Non-small Cell Lung Cancer treatment 1 unknown_status NCT03732482
Temozolomide Combine With Intensity Modulated Radiation Therapy With Simultaneous Integrated Boost for Non Small Cell Lung Cancer Brain Metastases treatment 2 / 3 unknown_status NCT00872482
A Study of Nimotuzumab in Combination With Radiation Therapy in Patients With Brain Metastases treatment 2 terminated NCT06523673
Stereotactic Body Radiotherapy for Oligo-Progression Metastatic Non-Small Cell Lung Cancer treatment 3 recruiting NCT05364073
Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations treatment 1 active_not_recruiting NCT03533127
A Study of LY01008 and Bevacizumab Combined With Paclitaxel and Carboplatin for Treatment of NaĂŻve Subjects With Metastatic or Recurrent Nonsquamous Non-small Cell Lung Cancer treatment 3 unknown_status NCT03926260
Early Assessment of Response to Treatment of Metastatic LUng Tumors Based on CIrculating Tumor DNA No drug interventions other Not Available completed NCT03469960
Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancEr treatment 3 active_not_recruiting NCT03656094
Chemotherapy With Pembrolizumab Continuation After Progression to PD-1/L1 Inhibitors treatment 2 unknown_status NCT05864794
Value of Screening MRI Brain in Stage IV Non-small Cell Lung Cancer No drug interventions screening Not Available recruiting NCT03424980
A Study to Evaluate Effectiveness and Safety of Tyrosine Kinase Inhibitors Not Available Not Available unknown_status NCT03265080
A Study of ADXS-NEO Expressing Personalized Tumor Antigens treatment 1 terminated NCT06585189
CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS4] Not Available Not Available completed NCT05599789
Pembrolizumab in Combination With Plinabulin and Docetaxel For Metastatic NSCLC After ICIs (KeyPemls-004) treatment 2 recruiting NCT06378892
A Study to Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Exclusively Extracranial Disease Progression on Lorlatinib treatment 2 recruiting NCT05215340
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations treatment 3 recruiting NCT06127940
K-SAB Trial - Sotorasib Followed by SBRT to 1-3 Lesions in Advanced NSCLC With KRASG12C Mutation No drug interventions treatment 1 recruiting NCT05472467
Camrelizumab Combination With SBRT and Concurrent Chemotherapy Treated Stage IV Oligometastatic Non-small Cell Lung Cancer treatment 2 unknown_status NCT02330367
Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010 in Patients With EGFR T790M Positive NSCLC treatment 1 / 2 unknown_status NCT02812667
Nivolumab in Combination With Plinabulin in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) treatment 1 active_not_recruiting NCT03679767
A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203) treatment 2 completed NCT06045767
T-Cell Repertoire Sequencing: Assessing Pembrolizumab Efficacy in Advanced Non-small Lung Cancer diagnostic 2 not_yet_recruiting NCT04187768
Immunological Profile Changes In Patients With Advanced Non-Small Cell Lung Cancer No drug interventions Not Available Not Available completed NCT02041468
Study to Evaluate Resistance Mechanisms and Real-world Pharmacoeconomics of Crizotinib in NSCLC Patients No drug interventions Not Available Not Available unknown_status NCT04697446
External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLC No drug interventions Not Available Not Available unknown_status NCT04599712
Pre-Approval Access With Amivantamab (JNJ-61186372) in Participants With Metastatic Non-Small Cell Lung Cancer Not Available Not Available approved_for_marketing NCT03215810
Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer treatment 1 completed NCT01380795
Feasibility of the Research for Mutation of K-ras and EGFR in CTCs From Metastatic Non Small Cells Bronchial Carcinomas No drug interventions screening 0 terminated NCT04994795
Predictive Multimodal Signatures Associated With Response to Treatment and Prognosis of Patients With Stage IV Non-small Cell Lung Cancer No drug interventions Not Available Not Available recruiting NCT06417814
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer treatment 3 not_yet_recruiting NCT05407155
Bevacizumab Plus Nab-paclitaxel and Platinum for Immunotherapy-treated Non-squamous Non-small Cell Lung Cancer treatment Not Available unknown_status NCT05265650
Study of BO-112 With Radiotherapy and Nivolumab for Metastatic Refractory NSCLC treatment 1 / 2 unknown_status NCT05668650
Double-blind Study to Evaluate the PK, Efficacy, Safety and Immunogenicity of MB12 Versus Keytruda® in Stage IV NSCLC treatment 3 recruiting NCT05607550
Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT) treatment 3 recruiting NCT04563338
An Exploratory Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer With Liver Metastases (INTEGRATE) treatment 2 recruiting NCT01356303
Docetaxel Combined With Cisplatin as First Line in Patients With Metastatic Non-small Cell Lung Cancer treatment 2 suspended NCT04965090
A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC) treatment 2 active_not_recruiting NCT02314364
A Trial of Integrating SBRT With Targeted Therapy in Stage IV Oncogene-driven NSCLC No drug interventions treatment 2 completed NCT03168464
Radiation and Immune Checkpoints Blockade in Metastatic NSCLC (BMS # CA209-632) treatment 1 / 2 terminated NCT05919264
FOG-001 in Locally Advanced or Metastatic Solid Tumors No drug interventions treatment 1 / 2 recruiting NCT04749602
Intrapleural Instillation of the Nivolumab in Cancer Patients With Pleural Effusion. treatment 2 completed NCT04166487
Plasma-Adapted First-Line Pembro In NSCLC treatment 2 active_not_recruiting NCT01935154
Efficacy Study of Vx001 Vaccine in NSCLC Patients treatment 2 completed NCT06517953
Befotertinib and Icotinib for NSCLC With Uncommon EGFR Mutations treatment 2 recruiting NCT05984277
A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer. treatment 3 recruiting NCT04923945
Savolitinib for Treating Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Patients treatment 3 recruiting NCT05546905
A Study in Patients With BRAF V600E-mutant Metastatic Non-small Cell Lung Cancer (OCTOPUS) No drug interventions Not Available Not Available recruiting NCT04111705
Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer treatment 2 active_not_recruiting NCT01717105
Observational Study to Characterize the Incidence of EGFR Mutation Positive and Advanced NSCLC Patients No drug interventions Not Available Not Available unknown_status NCT02035683
PET/CT Scan as a Tool to Rationalize the Treatment of of Advanced NSCLC Patients Undergoing First Chemotherapy No drug interventions treatment Not Available active_not_recruiting NCT01936961
Study of Immunochemotherapy +/- Hypofractionated Radiation for Complete Response in Solid Tumors No drug interventions treatment Not Available withdrawn NCT06279728
Medical Access Program for Datopotamab Deruxtecan in NSCLC Patients Not Available Not Available available NCT03319628
First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b treatment 1 / 2 active_not_recruiting NCT03334071
Exercise Intervention During Chemotherapy in Advanced Lung Cancer Patients No drug interventions treatment Not Available unknown_status NCT03224871
UCDCC#269: A Pilot Study of Interlesional IL-2 and RT in Patients With NSCLC. treatment 0 completed NCT04504071
Dacomitinib in Lung Cancer With Uncommon EGFR Mutations treatment 2 unknown_status NCT04621188
Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS) treatment 2 recruiting NCT03976856
Safety and Efficacy of Genolimzumab (GB226) in Combination With Fruquintinib treatment 1 unknown_status NCT01798485
A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC treatment 3 terminated NCT02843815
Combination of Cryosurgery and NK Immunotherapy for Advanced Non-Small Cell Lung Cancer No drug interventions treatment 1 / 2 completed NCT02443337
A Study of LY3023414 and Necitumumab in Squamous Lung Cancer treatment 2 terminated NCT02162537
Therapeutic Strategies in Patients With Non-squamous Non-small Cell Lung Cancer With Brain Metastases other 3 terminated NCT04163432
Staggered, Chemo-Immunotherapy With Durvalumab, MEDI4736 Pemetrexed & Carboplatin (PC) for Metastatic Non-Squamous NSCLC treatment 2 recruiting NCT05555732
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07) treatment 3 recruiting NCT06212752
A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension treatment 3 active_not_recruiting NCT03445000
ALEctinib for the Treatment of Pretreated RET-rearranged Advanced Non-small Cell Lung Cancer treatment 2 terminated NCT05167500
Efficacy & Safety Study of Lorlatinib in ALK/ROS1 Metastatic NSCLC Patients With Compassionate Use Treatment Not Available Not Available completed NCT03007875
High-activity Natural Killer Immunotherapy for Small Metastases of Non-small Cell Lung Cancer No drug interventions treatment 1 / 2 completed NCT03353675
A Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With the Therapeutic Vaccine Named TG4010 and Nivolumab in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC) treatment 2 completed NCT02857270
A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer treatment 1 completed NCT05117242
Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer treatment 2 active_not_recruiting NCT05676749
C-TIL051 in Non-Small Cell Lung Cancer treatment 1 recruiting NCT04069936
Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLC treatment 2 terminated NCT01658813
5-Fluorouracil Followed by Interferon-alfa-2b in Previously-treated Metastatic Gastrointestinal, Kidney, or Lung Cancer treatment 2 completed NCT01848613
Study of Patient Preference for Oral or Intravenous Vinorelbine in the Treatment of Advanced NSCLC treatment 4 completed NCT06060613
Safety and Efficacy of OBX-115 in Advanced Solid Tumors No drug interventions treatment 1 / 2 recruiting NCT03956641
Evolution of the Physical Condition in Treated Cancer Patients No drug interventions supportive_care Not Available unknown_status NCT02639234
Vigil™ + Nivolumab in Advanced Non-Small Cell Lung Cancer treatment 2 withdrawn NCT02418234
T790M Mutation on ctDNA in Patients With NSCLC After EGFR-TKI Failure No drug interventions Not Available Not Available completed NCT04394624
Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab or Ramucirumab and Pembrolizumab in Pretreated Patients With NSQ NSCLC (CARMEN-LC04) treatment 2 active_not_recruiting NCT04613596
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7 treatment 2 / 3 recruiting NCT04410796
Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers treatment 2 recruiting NCT04685135
Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation treatment 3 active_not_recruiting NCT00806286
Study of Carboplatin/Paclitaxel With or Without Investigational Drug (CS-7017) in Subjects With Metastatic Non-small Cell Lung Cancer treatment 2 completed NCT01405586
MILES-3: Cisplatin in Combination With Gemcitabine for Elderly Patients With Lung Cancer treatment 3 active_not_recruiting NCT06428422
The Impact of Probiotic on Survival and Treatment Response in Metastatic Non-small Cell Lung Cancer Patients No drug interventions treatment Not Available recruiting NCT04863248
Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Docetaxel for Metastatic Non-Small Cell Lung Cancer (NSCLC) (PRESERVE 4) treatment 2 terminated NCT01348126
Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer treatment 2 / 3 terminated NCT04331626
Low-dose Gemcitabine Combined With Nivolumab for Second-line and Above Line Treatment of NSCLC treatment 4 unknown_status NCT02818426
Universal Cancer Peptide-based Vaccination in Metastatic NSCLC treatment 1 / 2 active_not_recruiting NCT03235765
Cancer Panel From Blood of Lung Cancer Patients No drug interventions Not Available Not Available unknown_status NCT02299765
Intercalating and Maintenance Gefitinib in Combination With Chemotherapy for Advanced EGFR-mutant NSCLC treatment 4 terminated NCT03732274
Phase 1b/2a, Open-label Study of Vactosertib in Combination With Durvalumab in Advanced NSCLC treatment 1 / 2 unknown_status NCT02705820
Switch Maintenance Pembrolizumab in Patients With NSCLC After First Line Platinum Doublet Chemotherapy treatment 2 active_not_recruiting NCT04884282
Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED) treatment 2 recruiting NCT04340882
Phase 2 DoceRamPem for Patients With Metastatic or Recurrent NSCLC Who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade treatment 2 recruiting NCT05657873
A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC) treatment 2 recruiting NCT01999673
Phase 3 Study of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Late-stage Non-squamous Non-small-cell Lung Cancer treatment 3 completed NCT03977194
Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy treatment 3 active_not_recruiting NCT01703091
A Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer treatment 2 completed NCT03808662
Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung No drug interventions treatment 2 active_not_recruiting NCT03386929
Survival Prolongation by Rationale Innovative Genomics treatment 1 / 2 terminated NCT06207292
Stereotactic Ablative Radiotherapy in Synchronous and Metachronous Oligo-Metastatic Non Small Cell Lung Cancer No drug interventions treatment Not Available recruiting NCT04470440
Thyroid Dysfunction and Nivolumab Reponse in NSCLC No drug interventions Not Available Not Available completed NCT01523340
A Prospective Observational Study Evaluating c-MET Expression and EGFR Gene Mutation Correlation With Erlotinib Response No drug interventions Not Available Not Available completed NCT02117167
SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients treatment 2 completed NCT03497767
A Randomised Phase II Trial of Osimertinib With or Without SRS for EGFR Mutated NSCLC With Brain Metastases treatment 2 completed NCT01320501
Experience of Erlotinib in Patients With Advanced Non-Small Cell Lung Cancer treatment 4 suspended NCT06216301
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC treatment 3 recruiting NCT04619004
HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer No drug interventions treatment 2 active_not_recruiting NCT02978404
Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases treatment 2 completed NCT03164772
Phase 1/2 Study of Combination Immunotherapy and Messenger Ribonucleic Acid (mRNA) Vaccine in Subjects With NSCLC treatment 1 / 2 completed NCT03133546
Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790M (BOOSTER) treatment 2 unknown_status NCT03846310
A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer treatment 1 active_not_recruiting NCT02622581
Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients No drug interventions Not Available Not Available recruiting NCT05223595
A Study of Gentuximab in Combination With Almonertinib in EGFR Mutation-positive Metastatic NSCLC treatment 1 unknown_status NCT01060514
Pazopanib + Vinorelbine in Non Small Cell Lung Cancer (NSCLC) and Breast Cancer treatment 1 terminated NCT05013450
Dupilumab_Metastatic NSCLC treatment 1 / 2 recruiting NCT03377023
Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer treatment 1 / 2 active_not_recruiting NCT01752023
A Randomized Phase II Study of SUBATM-itraconazole in Patients With Untreated Squamous NSCLC. treatment 2 terminated NCT05800223
Armatinib Alone or in Combination With SRT for Brain Metastases EGFR-mutated Non-small Cell Lung Cancer treatment 3 recruiting NCT05566223
CISH Inactivated TILs in the Treatment of NSCLC treatment 1 / 2 not_yet_recruiting NCT05635708
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer treatment 2 recruiting NCT05236608
A Study to Evaluate the Combination of Nivolumab With ADG106 in Metastatic NSCLC treatment 1 / 2 unknown_status NCT06066138
A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing treatment 1 not_yet_recruiting NCT03611738
Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC treatment 1 active_not_recruiting NCT01966003
Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer treatment 3 completed NCT04614103
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer treatment 2 recruiting NCT03035890
Hypofractionated Radiation Therapy to Improve Immunotherapy Response in Non-Small Cell Lung Cancer No drug interventions treatment Not Available completed NCT02922764
A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer treatment 1 active_not_recruiting NCT01471964
Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotinib to Treat Non-Small Cell Lung Cancer treatment 1 / 2 terminated NCT02228421
Study to Evaluate Real-world Pharmacoeconomics of Crizotinib in NSCLC Patients No drug interventions Not Available Not Available terminated NCT04233021
Study of Osimertinib in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation treatment 2 active_not_recruiting NCT06343402
Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer treatment 1 recruiting NCT06106802
Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment treatment 2 not_yet_recruiting NCT01705184
Re-introduction of Pemetrexed and Cisplatin With Prolonged Angiogenic Blocking by Bevacizumab in Advanced Lung Cancer. treatment 2 completed NCT02019979
Metformin and Carbohydrate Restriction With Platinum Based Chemotherapy In Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NS-NSCLC) treatment 2 terminated NCT04466917
A Study of ABP 215 Versus Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung Cancer treatment 3 withdrawn NCT03158883
UCDCC#270: Avelumab and Stereotactic Ablative Radiotherapy in Non-responding and Progressing NSCLC Patients treatment 0 completed NCT03819465
A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC treatment 1 active_not_recruiting